Orbimed Advisors LLC, Director at BlossomHill Therapeutics, Inc. (BLSM), bought 625,000 shares at $16.00 ($10.0M) on 2026-08-10, disclosed to the SEC on 2026-08-12.
Orbimed Advisors LLC executed a $10 million insider purchase of 625,000 shares at $16.00, marking the largest ever transaction for BlossomHill Therapeutics and signaling strong institutional conviction.
The shares were purchased at $16.00, which is 3.67% below the 52-week high of $16.90, placing the trade near the upper end of the stock's recent trading range.
The transaction represents the largest insider purchase in the company's history, potentially signaling institutional confidence ahead of upcoming clinical data releases or corporate milestones.
The company has a market capitalization of approximately $472 million, which typically implies higher volatility and liquidity risk compared to larger peers.
Nothing distinguishes this filing.
| Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| SION | SELL | 2026-07-09 | $3.9M | — | Filing → |
| SION | SELL | 2026-07-02 | $5.3M | — | Filing → |